
-continued

Tyr	Thr	Cys	Asn	Val	Asp	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys
85								90						95	
Arg	Val	Glu	Ser	Lys	Tyr	Gly	Pro	Pro	Cys	Pro	Pro	Cys	Pro	Ala	Pro
100							105					110			
Glu	Phe	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys
115							120					125			
Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val
130							135				140				
Asp	Val	Ser	Gln	Glu	Asp	Pro	Glu	Val	Gln	Phe	Asn	Trp	Tyr	Val	Asp
145							150				155			160	
Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Phe
165							170				175				
Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp
180							185				190				
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Gly	Leu
195							200				205				
Pro	Ser	Ser	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg
210							215				220				
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Gln	Glu	Glu	Met	Thr	Lys
225							230				235			240	
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp
245							250				255				
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys
260							265				270				
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser
275							280				285				
Arg	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Glu	Gly	Asn	Val	Phe	Ser
290							295				300				
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	Arg	Phe	Thr	Gln	Lys	Ser
305							310				315			320	
Leu	Ser	Leu	Ser	Leu	Gly	Lys									
					325										

1. A bispecific antigen-binding molecule comprising a first antigen-binding domain that binds human APLP2 and a second antigen-binding domain that binds human HER2.
2. The bispecific antigen-binding molecule of claim 1, wherein the second antigen-binding domain binds human cells expressing human HER2.
3. The bispecific antigen-binding molecule of claim 1, wherein the first antigen-binding domain binds with low affinity to APLP2.
4. The bispecific antigen-binding molecule of claim 1, wherein each of the first antigen-binding domain and the second antigen-binding domain is fully human.
5. The bispecific antigen-binding molecule of claim 1, wherein the antigen-binding molecule binds both human APLP2 and human HER2 expressed on a cell and induces APLP2 internalization and/or degradation of HER2 in that cell.
6. The bispecific antigen-binding molecule of claim 1, wherein the antibody is not internalized by cells that express human APLP2 but do not express human HER2.
7. The bispecific antigen-binding molecule of claim 1, wherein the antibody is fully human.
8. The bispecific antigen-binding molecule of claim 1, wherein the first antigen-binding domain binds with low affinity to APLP2 and the second antigen-binding domain binds with high affinity to HER2 such that affinity of the second antigen-binding domain to HER2 increases the avidity of the first antigen-binding domain to APLP2.
9. The bispecific antigen-binding molecule of claim 1, wherein the first antigen-binding domain binds human APLP2 with a KD of about 100 nM to about 1 μ M, as measured by surface plasmon resonance, or equivalent assay.
10. The bispecific antigen-binding molecule of claim 1, wherein the first antigen-binding domain binds human APLP2 with a KD of about 100 nM to about 200 nM, as measured by surface plasmon resonance, or equivalent assay.
11. The bispecific antigen-binding molecule of claim 1, wherein the first antigen-binding domain binds human